
    
      The aim of this phase III study was to evaluate the efficacy and safety of additional
      combined CKD-501 administration for 24 weeks in patients with type 2 diabetes who were not
      adequately controlled for blood glucose by the combination of D150 and D745 25mg .

      Furthermore, the extension study for additional 28 weeks is designed to confirm long term
      safety of actual drug as an oral hypoglycemic agent.
    
  